Design, synthesis, and biological evaluation of novel pyrrolo[1,2-a]pyrazine derivatives. 2019

Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea.

A pyrrolo[1,2-a]pyrazine-based chemical territory was expanded via construction of new chemical library with distinctive substitution patterns, which was made possible by regiodivergent electrophilic acylation followed by aldol condensation. Biological screening of the compounds in this class revealed that the viability of human lymphoma U937 cells was strongly inhibited by 6b with a methoxy group at the o-position of the aromatic ring, but not by compounds 6t-w bearing a halogen at the o-position. Furthermore, 6x having a 2,4-dimethoxyphenyl group inhibited the survival of U937 cells more potently than 6b. In contrast, 6y possessing a 2,5-dimethoxyphenyl moiety did not show effective inhibition, implying the importance of orientation of the substituent(s) around the benzene ring. The anticancer action of 6x with safe therapeutic window could be associated with the FTase-p38 signaling axis.

UI MeSH Term Description Entries
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D020298 U937 Cells A human cell line established from a diffuse histiocytic lymphoma (HISTIOCYTIC LYMPHOMA, DIFFUSE) and displaying many monocytic characteristics. It serves as an in vitro model for MONOCYTE and MACROPHAGE differentiation. Cell, U937,Cells, U937,U937 Cell

Related Publications

Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
July 2014, Archiv der Pharmazie,
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
October 2014, Bioorganic & medicinal chemistry,
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
February 2017, Molecules (Basel, Switzerland),
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
September 2020, European journal of medicinal chemistry,
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
January 2022, Medicinal chemistry (Shariqah (United Arab Emirates)),
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
January 2017, Chemistry Central journal,
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
November 2013, Bioorganic & medicinal chemistry letters,
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
June 2015, European journal of medicinal chemistry,
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
January 2003, Acta poloniae pharmaceutica,
Jinwoo Kim, and Mikyung Park, and Jiwon Choi, and Dileep Kumar Singh, and Ho Jeong Kwon, and Seong Hwan Kim, and Ikyon Kim
October 2015, Chemical biology & drug design,
Copied contents to your clipboard!